Drug Shortage Report for SANDOZ RIVASTIGMINE
| Report ID | 230768 |
| Drug Identification Number | 02324563 |
| Brand name | SANDOZ RIVASTIGMINE |
| Common or Proper name | RIVASTIGMINE |
| Company Name | SANDOZ CANADA INCORPORATED |
| Market Status | MARKETED |
| Active Ingredient(s) | RIVASTIGMINE |
| Strength(s) | 1.5MG |
| Dosage form(s) | CAPSULE |
| Route of administration | ORAL ORAL |
| Packaging size | 56HGC |
| ATC code | N06DA |
| ATC description | ANTI-DEMENTIA DRUGS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2024-06-17 |
| Estimated end date | |
| Actual end date | 2024-12-10 |
| Shortage status | Resolved |
| Updated date | 2024-12-11 |
| Company comments | Discontinued |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
| Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v8 | 2024-12-11 | English | Compare |
| v7 | 2024-12-10 | French | Compare |
| v6 | 2024-12-10 | English | Compare |
| v5 | 2024-09-03 | French | Compare |
| v4 | 2024-09-03 | English | Compare |
| v3 | 2024-06-18 | English | Compare |
| v2 | 2024-06-17 | French | Compare |
| v1 | 2024-06-17 | English | Compare |
Showing 1 to 8 of 8